Skip to main content
main-content

Type 2 diabetes and cardiovascular disease

Patient case study

Cardiovascular risk reduction in type 2 diabetes

Heart and stethoscope

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this case study [read more].

Get more on: Cardiovascular disease | SGLT2 inhibitors | GLP-1 receptor agonists

medwireNews editor's pick

Gap in cardiovascular risk not closing for people with type 2 diabetes

Heartbeat

The incidence of coronary heart disease has declined in recent years but people with type 2 diabetes continue to have a significantly greater risk than those without, Scottish data show.

medwireNews editor's pick

High mental illness burden in young-onset type 2 diabetes

Hospital

Over a third of time spent in hospital before the age of 40 years by patients who develop type 2 diabetes by this age is due to mental illness, report researchers.

medwireNews editor's pick

Older type 2 diabetes patients may derive greatest liraglutide benefits

Elderly diabetic patient (symbolic image with models)

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

Expert opinion editorial

What have I learned from cardiovascular outcome trials?

Medication arranged in a heart shape

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future [read more]

Get more on: Cardiovascular disease | Type 2 diabetes | Expert opinion

medwireNews editor's pick

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

New Content Item

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

medwireNews editor's pick

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Heartbeat

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

medwireNews editor's pick

Marked reduction in vascular events in diabetes patients after bariatric surgery

Obesity surgery

An observational study published in JAMA demonstrates a substantial reduction in the risk for hard cardiovascular endpoints in obese patients with type 2 diabetes who have undergone bariatric surgery.

medwireNews editor’s pick

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Heart and ECG_Fotolia_287046_Subscription_XL

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

medwireNews editor's pick

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

Heartbeat

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

medwireNews

03-18-2019 | Dapagliflozin | News

DECLARE analyses show dapagliflozin benefits for reduced ejection fraction, prior MI subgroups

Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.

03-17-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

03-12-2019 | Hypoglycemia | DUKPC 2019 | News

Nurse-led intervention can reduce mortality risk after severe hypoglycemia

Assigning people with type 2 diabetes to 3 months of focused care with a specialist diabetes nurse after an episode of severe hypoglycemia reduces their risk for mortality over the following few years, research shows.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-28-2018 | Diabetic cardiomyopathy | Article

Cardiovascular risk reduction over time in patients with diabetes or pre-diabetes undergoing bariatric surgery: data from a single-center retrospective observational study

Rubio-Almanza M, Cámara-Gómez R, Hervás-Marín D et al. BMC Endocr Disord 2018; 18: 90. doi: 10.1186/s12902-018-0317-4

11-21-2018 | Cardiovascular disorders | Review | Article

Unrecognised cardiovascular disease in type 2 diabetes: Is it time to act earlier?

Schernthaner G et al. Cardiovasc Diabetol 2018; 17: 145. doi: 10.1186/s12933-018-0788-7

11-10-2018 | Retinopathy | Article

Diabetic retinopathy grade as a predictive marker of severity of cardiovascular disease and mortality: DIVERSE Study Group

Shah K et al. Int J Diabetes Dev Ctries 2018. doi: 10.1007/s13410-018-0699-x

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

image credits